Hyperparathyroidism 2

Common Name(s)

Hyperparathyroidism 2

Hyperparathyroidism-jaw tumor syndrome is a rare autosomal dominant disorder characterized by synchronous or metachronous occurrence of primary hyperparathyroidism, ossifying fibroma of the maxilla and/or mandible, renal tumor, and uterine tumors. It is associated with increased risk of parathyroid cancer (summary by {16:Shibata et al., 2015}). For a discussion of genetic heterogeneity of hyperparathyroidism, see HRPT1 ({145000}).
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Hyperparathyroidism 2" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Hyperparathyroidism 2" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Hyperparathyroidism 2" returned 9 free, full-text research articles on human participants. First 3 results:

Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis.
 

Author(s): Richa Pandey, Julia B Zella, Jinge G Zhu, Lori A Plum, Margaret Clagett-Dame, William J Blaser, Wendy Bedale, Hector F DeLuca, Daniel W Coyne

Journal: Drugs R D. 2017 Dec;17(4):597-605.

 

2-Methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D (DP001 or 2MD) is a novel, potent 1α-hydroxylated vitamin D analog that binds to the vitamin D receptor and suppresses parathyroid hormone synthesis and secretion with potential for an improved safety profile compared to existing ...

Last Updated: 31 Dec 1969

Go To URL
Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological study.
 

Author(s): Pierre Filipozzi, Carole Ayav, Willy Ngueyon Sime, Emmanuelle Laurain, Michèle Kessler, Laurent Brunaud, Luc Frimat

Journal:

 

To define groups of patients according to the changes of biochemical parameters, that is, serum calcium, phosphate and parathyroid hormone (PTH), over a 2-year follow-up period using group-based multi-trajectory modeling (GBMM) among a cohort of dialysis patients with newly diagnosed ...

Last Updated: 31 Dec 1969

Go To URL
Clinical efficacy of 2-phase versus 4-phase computed tomography for localization in primary hyperparathyroidism.
 

Author(s): Adriana G Ramirez, Amber L Shada, Allison N Martin, Prashant Raghavan, Christopher R Durst, Sugoto Mukherjee, John R Gaughen, David A Ornan, John B Hanks, Philip W Smith

Journal: Surgery. 2016 09;160(3):731-7.

 

Four-dimensional computed tomography is being used increasingly for localization of abnormal glands in primary hyperparathyroidism. We hypothesized that compared with traditional 4-phase imaging, 2-phase imaging would halve the radiation dose without compromising parathyroid localization ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Hyperparathyroidism 2" returned 1 free, full-text review articles on human participants. First 3 results:

Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
 

Author(s): Nobuo Nagano, Edward F Nemeth

Journal: J. Pharmacol. Sci.. 2005 Mar;97(3):355-60.

 

Circulating levels of calcium ion (Ca(2+)) are maintained within a narrow physiological range mainly by the action of parathyroid hormone (PTH) secreted from parathyroid cells. Parathyroid cells can sense small fluctuations in plasma Ca(2+) levels by virtue of a cell surface Ca(2+) ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

A Single-dose Study in Paediatric Subjects Aged 2 to Less Than 18 Years With (sHPT) Receiving Haemodialysis
 

Status: Recruiting

Condition Summary: Chronic Kidney Disease, Secondary Hyperparathyroidism

 

Last Updated: 16 Aug 2018

Go to URL
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
 

Status: Recruiting

Condition Summary: Secondary Hyperparathyroidism Due to Renal Causes; Chronic Kidney Diseases; Vitamin D Deficiency; Stage 5 Chronic Kidney Disease

 

Last Updated: 25 Jul 2018

Go to URL